International Journal of Hematology and Oncology 2021, Vol 31, Num 4 Page(s): 130-137
IMMUNOHISTOCHEMICAL ANALYSIS OF PROSTATE SPESIFIC ANTIGEN IN BREAST CANCER AND CORRELATION WITH CLINICAL PARAMETERS

CELALETTİN CAMCI1, SEMRA PAYDAŞ1, SUZAN ZORLUDEMİR1, BURHAN HAZAR1, BERKSOY ŞAHİN1

Gaziantep University Medical Faculty Department of Oncology, Gaziantep

Keywords: breast cancer, immunohistochemistry, prognosis, psa
Breast cancer is the most common cancer among women and although important improvements achieved in the treatment, it is still the leading cause of cancer deaths. In this study we investigated correlation between PSA immunohistochemical staining and clinicopathologic parameters including age, histopathologic type, axillary node involvement, estrogen receptor (ER) status, menopausal status, stage (TNM) and therapy patients with breast cancer. Sixty six women who had documented breast cancer were included in this study. Tumor tissue samples were stained with hematoxilen-eosin for routine histopathologic evaluation and grading. Monoclonal mouse anti-human oestrogen receptor kit (DAKO code#7047; 1:50 dilution) was used for oestrogen receptor analysis. PSA (F-6) mouse polyclonal antibody kit (DAKO cat#A0562; 1:400 dilution) was used for PSA evaluation. Staining was classified as 1+ to 3+ by pathologist. Forty-one out of 66 patients were premenapousal, mean age was 40.12±5.42(25-50) and 58.36±8.79 (45-85) for pre- and postmenapousal patients, respectively. Infiltrative ductal carcinoma was detected in 55 patients (in whom 64% premenapousal), estrogen receptor positivity was determined in 33 patients (in whom 64% premenapousal). Distribution of the patients according to TNM staging was as follows: eleven patients in stage 1, thirty-four patients in stage 2, seventeen patients in stage 3 and four patients in stage 4. Thirty-six cases had axillary lymph node involvement, and 18 of these had equal or less than 3 lymph node involvement. Grade I tumor was detected 7 cases (3 premenapousal), grade II tumor was detected in 42 cases (24 premenapousal) and 17 cases had grade III tumor according to modified Bloom-Richardson classification. Except for a negative correlation between PSA staining and grade of the tumor (p=0.005, r= -0.4551), there was no relationship among other parameters and PSA expression. In addition, relapse free survival and relapse sites also showed no correlation with PSA staining. Discussion: PSA can be produced not only from prostate but also from breast, lung, and uterine cancers. Preliminary data suggested that patients with breast tumors positive for PSA may have better prognosis compared to those with PSA-negative breast tumors. Following studies failed to show this prognostic significance. On the contrary there was some data about poor response to tamoxifen therapy in the second line treatment. In scope of our results, we concluded that PSA is not a good prognostic parameter in breast cancer.